GlaxoSmithKline plc and Vir Biotechnology, Inc announced an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant (B.1.1.529). The preclinical data was generated through pseudo-virus testing of the combined known mutations of the Omicron variant, which included the maximum number of changes (37 mutations) identified to date in the spike protein.
- Read more about Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/preclinical-studies-demonstrate-sotrovimab-retains-activity-against-the-full-combination-of-mutations-in-the-spike-protein-of-the-omicron-sars-cov-2-variant
No comments:
Post a Comment